Why FairJourney Bio

Why FairJourney Bio

The integrated antibody expert from discovery to IND

Most antibody discovery companies hand off your molecule. FairJourney Bio carries it. From first library design to IND filing, one partner manages every stage — with the scientific depth to de-risk each one.

Discuss your discovery programme

The integrated antibody expert from discovery to IND

Most antibody discovery companies hand off your molecule. FairJourney Bio carries it. From first library design to IND filing, one partner manages every stage — with the scientific depth to de-risk each one.

Discuss your discovery programme

The integrated antibody expert from discovery to IND

Most antibody discovery companies hand off your molecule. FairJourney Bio carries it. From first library design to IND filing, one partner manages every stage — with the scientific depth to de-risk each one.

Discuss your discovery programme

>1,400

Projects completed

>250

industry partners

>19

partner assets entered clinical trials

>5,000

libraries generated 14 years. 300 scientists. One destination: IND.

>460,000

real-word sequences solved

>21,000

antibodies produced

>250

scientists in Europe and US

>60

PhDs in mAb research

>14

years of corporate experience

What makes FairJourney Bio different

Antibody drug development is full of handover risks. Each time your molecule moves between vendors, you absorb delays, misaligned goals, and rework. FairJourney Bio was built to eliminate these gaps — not by doing everything in-house, but by being the single accountable partner that connects the right capabilities at each stage.

A complete toolbox for any biological question 

You shouldn't have to shape your programme around a single technology. FairJourney Bio brings a broad range of discovery approaches to every target, whether the answer lies in display, single B-cell, or a specialised workflow. When a target is difficult, we explore parallel pathways and follow the one that delivers the best solution for your programme.

Fully integrated, Discovery to IND

FairJourney Bio's integrated model connects antibody discovery directly to CMC, saving partners up to 6 months on the path to first clinical batch. Our project managers span both phases, eliminating the handover friction that derails timelines at the Discovery/CMC interface.

Format-agnostic discovery platforms

Antibody programmes no longer follow a single format. FairJourney Bio's discovery platforms are designed for the full modality spectrum: conventional IgGs, bispecifics, nanobodies, multi-domain constructs, and emerging formats. Partners are not constrained by platform limitations at the point where candidate selection matters most.

In-house characterization and lead optimization

Leads are profiled against your Target Product Profile (TPP) from early screening. Biophysical and biochemical characterization is performed in-house, enabling developability and manufacturability assessment before candidates advance — not after.

Single-party 

accountability

One contract. One project manager. One invoice. FairJourney Bio manages vendor selection, pre-negotiated pricing, and IND writing under a single framework. Partners retain access to best-in-class CLD and CDMO partners, without the complexity of direct management.

Up to 6 months faster to first clinical batch

FairJourney Bio's integrated Discovery-to-CMC model eliminates the delays most commonly caused by vendor handovers, misaligned goals, and reactive re-work. The result is a first-in-human timeline of 12–14 months from confirmed lead candidate — saving partners up to 6 months compared to fragmented multi-vendor programmes.

Built to solve the hardest problems in antibody development

Every R&D programme encounters the same structural challenges. FairJourney Bio's platform was architected around them.

R&D Challenge

How FairJourney Bio Addresses It

Partner Benefit

Complex & 

novel formats

Format-agnostic discovery technologies covering mAbs, bispecifics, nanobodies, and multi-domain formats

Broadest candidate basis — no modality left behind

Timelines

Holistic R&D approach with in-house project management; seamless Discovery-to-CMC handover saving up to 6 months

Faster IND submission with fewer surprises

Developability & 

efficacy

In-house characterization and optimization platforms; lead candidates profiled against Target Product Profile (TPP) from day one

Customized leads — developability baked in, not bolted on

Budget

Single-party contracting, pre-negotiated pricing, and co-ownership structures available

Capital-efficient innovation; one invoice, full cost control

CMC challenges

In-house protein production and cell lines; seamless Research Cell Bank (RCB) to clinical batch transitione

Elimination of third-party handover risks at the most critical juncture

Team and expertise

Scientific depth at every stage

FairJourney Bio's team of more than 250 scientists includes more than 60 PhDs in monoclonal antibody research, spanning discovery, characterization, process development, and regulatory science. The team spans operations in Europe and the US, with 18 nationalities represented and 64% of leadership positions held by women.

Scientific experts on the advisory board include researchers with experience at Genmab, AstraZeneca, Abbott, AbbVie, ETH Zürich, and Scripps Research. The supervisory board includes former senior leaders from Pfizer, Boehringer Ingelheim, Amgen, and Alexion..

Team and expertise

Scientific depth at every stage

FairJourney Bio's team of more than 250 scientists includes more than 60 PhDs in monoclonal antibody research, spanning discovery, characterization, process development, and regulatory science. The team spans operations in Europe and the US, with 18 nationalities represented and 64% of leadership positions held by women.

Scientific experts on the advisory board include researchers with experience at Genmab, AstraZeneca, Abbott, AbbVie, ETH Zürich, and Scripps Research. The supervisory board includes former senior leaders from Pfizer, Boehringer Ingelheim, Amgen, and Alexion..

Team and expertise

Scientific depth at every stage

FairJourney Bio's team of more than 250 scientists includes more than 60 PhDs in monoclonal antibody research, spanning discovery, characterization, process development, and regulatory science. The team spans operations in Europe and the US, with 18 nationalities represented and 64% of leadership positions held by women.

Scientific experts on the advisory board include researchers with experience at Genmab, AstraZeneca, Abbott, AbbVie, ETH Zürich, and Scripps Research. The supervisory board includes former senior leaders from Pfizer, Boehringer Ingelheim, Amgen, and Alexion..

Partnership model

Flexible models for every stage of growth

FairJourney Bio structures partnerships to match the reality of your programme and pipeline. Engagement models include:

  • Service-only engagements for defined project scopes

  • Co-development structures with aligned incentives

  • Co-ownership arrangements for asset-level partnerships

  • Full Discovery-to-IND integrated programmes with single-party accountability

Whether you are advancing a first asset or scaling a multi-programme pipeline, the commercial structure is built around your requirements, not a standard menu.

Partnership model

Flexible models for every stage of growth

FairJourney Bio structures partnerships to match the reality of your programme and pipeline. Engagement models include:

  • Service-only engagements for defined project scopes

  • Co-development structures with aligned incentives

  • Co-ownership arrangements for asset-level partnerships

  • Full Discovery-to-IND integrated programmes with single-party accountability

Whether you are advancing a first asset or scaling a multi-programme pipeline, the commercial structure is built around your requirements, not a standard menu.

Partnership model

Flexible models for every stage of growth

FairJourney Bio structures partnerships to match the reality of your programme and pipeline. Engagement models include:

  • Service-only engagements for defined project scopes

  • Co-development structures with aligned incentives

  • Co-ownership arrangements for asset-level partnerships

  • Full Discovery-to-IND integrated programmes with single-party accountability

Whether you are advancing a first asset or scaling a multi-programme pipeline, the commercial structure is built around your requirements, not a standard menu.

Fullspectrum Characterization

fullspectrum-characterization

0

AnyFormat Manufacturing

anyformat-manufacturing

0

DeepDesign Engineering

deepdesign-engineering

0

FunctionInsight Assays

functioninsight-assays

0

B-Cell Navigator

b-cell-navigator

0

Solutions

solutions

1

Platforms & Technologies

platforms-technologies

0

Why FJBio

why-fjbio

0

Events & Resources

events-resources

0

Company

company

0

About

about

0

Antibody Discovery

antibody-discovery

0

Protein Production

protein-production

0

AtomicLevel Cryo-EM

atomic-level-cryo-em

0

FastTrack IND

fasttrack-ind

0

Biologistics

biologistics

0

Leadership

leadership

0

Careers

careers

0

News & Insights

news-insights

0

Case Studies

case-studies

0

Fact Sheets

fact-sheets

0

CellCraft Solutions

cellcraft-solutions

0

Cryo-EM

cryo-em

0

Display Platforms

display-platforms

0

Events

events

0

Library Diversity

library-diversity

0

MultiPath Discovery

multipath-discovery

0

Publications & Posters

publications-posters

0

Resources

resources

0

Screening | Analytics | Data Engines

screening-analytics-data-engines

0

Single B-Cell Screening

single-b-cell-screening

0

The Antibody Series Conference

the-antibody-series-conference

0

Tumbler™

tumbler

0

Webinars

webinars

0

White papers

whitepapers

0

Contact Us

contact-us

0